Stem cell infusions aim to tame COVID-19 inflammation

NCT ID NCT04362189

Terminated Disease control Sponsor: Hope Biosciences Research Foundation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether infusions of stem cells from donated fat tissue could help people with COVID-19. The trial planned to enroll 48 adults and compare four doses of stem cells against a placebo. The goal was to see if the treatment could reduce inflammation and improve oxygen levels. However, the study was terminated early, so the full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs)
What this could lead to: If it works, this could point toward a treatment that reduces severe inflammation and helps COVID-19 patients recover faster.
What could go wrong: This trial was terminated early with only 48 participants, so results are limited. Stem cell therapies are still experimental and may not prove effective or safe for COVID-19.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Coronavinae infectious disease COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19

Contacts and locations

Show contact details

Locations

River Oaks Hospital and Clinics

Houston, Texas, 77027, United States
United Memorial Medical Center

Houston, Texas, 77091, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.